



Diagnosis, the missing key to health

FIND is a global non-profit organization that drives innovation in the development and delivery of diagnostics to combat major diseases affecting the world's poorest populations.

Diagnostics often do not exist, are inaccessible, or cost too much. Despite being pivotal for guiding the best treatment for individual patients; for preventing the spread of disease and antimicrobial resistance; and for enhancing surveillance for early disease detection and monitoring – diagnostics remain under-resourced and overlooked.

We are the only WHO Collaborating Centre in diagnostics, with priorities clearly aligned with the global public health community. We turn complex diagnostic challenges into simple solutions through unique partnerships with the public, private and non-profit sectors.

We have 120 staff based in Geneva and 4 regional hubs, working with our partners on over 70 projects across six disease areas. Our work bridges R&D to access: we have deep technical and practical experience in definition of needs, development of fit-for-purpose products, generation of evidence for regulators and policy-makers, analysis of market dynamics, introduction of new products, and strengthening of laboratory systems.

Since 2003, we have been instrumental in the development of 24 new diagnostic tools. Over 50 million FIND-supported products have been provided to 150 low- and middle-income countries since the start of 2015. Our work has been transformative in the diagnosis of tuberculosis and malaria, and helped bring sleeping sickness elimination within reach.

In the next few years we are seeking to achieve multiple diagnostic breakthroughs, from point-of-care tests that will help patients access appropriate treatment for diseases including tuberculosis and hepatitis C, to advances in digital tools to make diagnostic data useful in low-resource settings for clinical care and surveillance.

CORE ACTIVITIES

Collaborating to define target product profiles

Shaping development of fit-for-purpose products

Supplying specimens and reagents to researchers and developers

Running clinical trials to generate data that inform regulatory and policy decisions

Supporting market sustainability

Conducting price negotiations

Strengthening laboratory systems

Training health workers

Promoting the value of diagnostics

BY 2020 WE AIM TO:

- **Develop a POC test for TB** to find the “missing millions” of undiagnosed patients and link them to appropriate care
- **Develop diagnostics that support WHO objectives** for three neglected tropical diseases (schistosomiasis, Buruli ulcer, leishmaniasis)
- **Evaluate a partnership-based flexible business model** that pairs assay developers with platform developers to provide comprehensive test menus and support global pandemic preparedness
 - **Introduce single-step screening test for hepatitis C**, including a self-test
 - **Develop POC tests** to combat antimicrobial resistance through responsible antibiotic use
 - **Bring to scale innovative software solutions** to drive diagnostic data use (e.g. electronic clinical decision aids)
- **Scale up innovative delivery models** in early adopter countries (e.g. POC tests for hepatitis C to reach key populations)
- **Support procurement of over 20 million FIND-supported tests** at global access price in LMICs every year
- **Ensure 1,000 health workers are trained** and 800 laboratories and testing sites strengthened every year

SUCCESS STORIES

We have been involved in the development and/or delivery of **every one of the 10 TB diagnostics** recommended by WHO.

We co-developed assays for GeneXpert, a point-of-care (POC) molecular platform that **has changed the landscape in TB diagnosis** and drug-susceptibility testing: time taken to obtain a test result has been reduced from months to less than 2 hours. GeneXpert is becoming the **mainstay of infectious disease diagnosis** in low-resource settings, used in more than 130 countries for diseases including HIV (early infant diagnosis), HPV, HCV, and Ebola – as well as TB.

We co-developed the first rapid diagnostic test (RDT) for sleeping sickness and supported its implementation in integrated screening strategies, which has been **central to sleeping sickness elimination efforts**: 16 African countries are on track to meet WHO targets.

We introduced a systematic, WHO-endorsed assessment of malaria RDTs to help countries buy quality tests, which has **transformed the malaria market** and enabled test-and-treat strategies for control: 96% of tests now meet quality standards – versus 23% in 2006.

BOARD OF DIRECTORS

Mark Kessel (CHAIRMAN)

Daniel Camus	Ilna Kickbusch
George F. Gao	Carlos Morel
David L. Heymann	Marcel Tanner
Andrew Jack	Sheila D. Tlou
Shobana Kamineni	Michael Watson

EXECUTIVE LEADERSHIP

Catharina Boehme (CHIEF EXECUTIVE OFFICER)
Zachary Katz (CHIEF ACCESS OFFICER)
Rangarajan Sampath (CHIEF SCIENTIFIC OFFICER)